Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel

Cancer Cell International

Ezharul Hoque Chowdhury³  Toshihiro Akaike³  Sharif Hossain³  Tahereh Fatemian²  Snigdha Tiash²  Diyana Salleh¹  Athirah Bakhtiar¹  Anthony Stanislaus¹ 

[1] Faculty of Medicine and Health Science, International Medical University (IMU), No. 126, Jalan 19/155B, Bukit Jalil, Kuala Lumpur, 57000, Malaysia;Jeffrey Cheah School of Medicine and Health Sciences, Monash University Sunway Campus, Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan, Malaysia;Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, 226-8501, Japan

关键词: Paclitaxel;    Doxorubicin;    Cisplatin;    Cervical cancer;    Calmodulin 1;    PLC-gamma-2;    siRNA;    Nanoparticle;    Carbonate apatite;   

Others  :  794872
DOI  :  10.1186/1475-2867-12-30

 received in 2012-01-30, accepted in 2012-06-18,  发布年份 2012

【 摘 要 】

Background

RNA interference (RNAi) is a powerful approach in functional genomics to selectively silence messenger mRNA (mRNA) expression and can be employed to rapidly develop potential novel drugs against a complex disease like cancer. However, naked siRNA being anionic is unable to cross the anionic cell membrane through passive diffusion and therefore, delivery of siRNA remains a major hurdle to overcome before the potential of siRNA technology can fully be exploited in cancer. pH-sensitive carbonate apatite has recently been developed as an efficient tool to deliver siRNA into the mammalian cells by virtue of its high affinity interaction with the siRNA and the desirable size distribution of the resulting siRNA-apatite complex for effective cellular endocytosis. Moreover, internalized siRNA was found to escape from the endosomes in a time-dependent manner and efficiently silence gene expression.

Results

Here we show that carbonate apatite-mediated delivery of siRNA against PLC-gamma-2 (PLCG2) and calmodulin 1 (CALM1) genes has led to the sensitization of a human cervical cancer cell line to doxorubicin- and paclitaxel depending on the dosage of the individual drug whereas no such enhancement in cell death was observed with cisplatin irrespective of the dosage following intracellular delivery of the siRNAs.

Conclusion

Thus, PLCG2 and CALM1 genes are two potential targets for gene knockdown in doxorubicin and paclitaxel-based chemotherapy of cervical cancer.

【 授权许可】

   
2012 Stanislaus et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]de Fougerolles AR: Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008, 19:125-132.
• [2]Gao K, Huang L: Nonviral methods for siRNA delivery. Mol Pharm 2009, 6:651-658.
• [3]Lee NS, Rossi JJ: Control of HIV-1 replication by RNA interference. Virus Res 2004, 102:53-58.
• [4]Grünweller A, Hartmann RK: RNA interference as a gene-specific approach for molecular medicine. Curr Med Chem 2005, 12:3143-3161.
• [5]Ito M, Kawano K, Miyagishi M, Taira K: Genome-wide application of RNAi to the discovery of potential drug targets. FEBS Lett 2005, 579:5988-5995.
• [6]Lu PY, Xie F, Woodle MC: In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005, 54:117-142.
• [7]Chowdhury EH: Nuclear targeting of viral and non-viral DNA. Expert Opin Drug Deliv 2009, 6:697-703.
• [8]Chowdhury EH: Strategies for tumor-directed delivery of siRNA. Expert Opin Drug Deliv 2011, 8:389-401.
• [9]Reischl D, Zimmer A: Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine 2009, 5:8-20.
• [10]Ryther RC, Flynt AS, Phillips JA, Patton JG: siRNA therapeutics: big potential from small RNAs. Gene Ther 2005, 12:5-11.
• [11]van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R: Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006, 34:1393-1397.
• [12]Dickerson EB, Blackburn WH, Smith MH, Kapa LB, Lyon LA, McDonald JF: Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 2010, 10:1-11. BioMed Central Full Text
• [13]Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
• [14]Brader S, Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004, 90:2-8.
• [15]Kahl CR, Means AR: Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr Rev 2003, 24:719-6.
• [16]Clapham DE: Calcium Signaling. Cell 2007, 131:1047-1058.
• [17]Colomer J, Means AR: Physiological roles of the Ca2+/CaM-dependent protein kinase cascade in health and disease. Subcell Biochem 2007, 45:169-214.
• [18]Hossain S, Stanislaus A, Chua MJ, Tada S, Tagawa Y, Chowdhury EH, Akaike T: Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J Control Release 2010, 147:101-108.
• [19]Stanislaus A, Hossain S, Chua MJ, Kunnath AP, Wen QC, Syakira SN, Siong GY, Loong SW, Othman I, Akaike T, Chowdhury EH: Fabrication and intracellular delivery of siRNA/carbonate apatite nano-composites for effective knockdown of cyclin B1 gene. Drugs Therp Studies 2011, 1:26-30.
• [20]Cowell CF, Döppler H, Yan IK, Hausser A, Umezawa Y, Storz P: Mitochondrial diacylglycerol initiates protein-kinase-D1-mediated ROS signalling. J Cell Sci 2009, 122:919-8.
• [21]Kim M, Jung J, Lee K: Roles of ERK, PI3 kinase, and PLC-γ pathways induced by overexpression of translationally controlled tumor protein in HeLa cells. Arch Biochem Biophys 2009, 485:82-87.
• [22]Li CJ, Heim R, Lu P, Pu Y, Tsien RY, Chang DC: Dynamic redistribution of calmodulin in HeLa cells during cell division as revealed by a GFP-calmodulin fusion protein technique. J Cell Sci 1999, 112:1567-1577.
• [23]Jang MK, Goo YH, Sohn YC, Kim YS, Lee SK, Kang H, Cheong J, Lee JW: Ca2+/calmodulin-dependent protein kinase IV stimulates nuclear factor-kappa B transactivation via phosphorylation of the p65 subunit. J Biol Chem 2001, 276:20005-20010.
• [24]Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cell 1990, 2:275-279.
• [25]Alberts DS, Garcia D, Mason-Liddil N: Cisplatin in advanced cancer of the cervix: an update. Semin Oncol 1991, 18:11-24.
• [26]Nishio K, Sugimoto Y, Fujiwara Y, Ohmori T, Morikage T, Takeda Y, Ohata M, Saijo N: Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II). J Clin Invest 1992, 89:1622-1628.
• [27]Kristensen G, Tropé C: Endometrial cancer: the management of high-risk disease. Curr Oncol Rep 2004, 6:471-475.
• [28]Nguyen HN, Nordqvist SR: Chemotherapy of advanced and recurrent cervical carcinoma. Semin Surg Oncol 1999, 16:247-250.
• [29]Thompson MG, Hickman JA: Doxorubicin interactions at the membrane: evidence for a biphasic modulation of inositol lipid metabolism. Eur J Cancer 1991, 27:1263-1268.
• [30]De Vincenzo R, Amadio G, Ricci C, Licameli A, Ferrandina G, Capelli G, Scambia G: Treatment of cervical cancer in Italy: strategies and their impact on the women. Vaccine 2009, 27:A39-A45.
• [31]Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008, 34:603-613.
• [32]Melander Gradin H, Marklund U, Larsson N, Chatila TA, Gullberg M: Regulation of microtubule dynamics by Ca2+/Calmodulin-dependent kinase IV/Gr-dependent phosphorylation of oncoprotein 18. Mol Cell Biol 1997, 17:3459-3467.
• [33]Gallagher BM: Microtubule-stabilizing natural products as promising cancer therapeutics. Curr Med Chem 2007, 14:2959-2967.